KNSA · Investment summary · as of 4 August 2026
Priced close to what the business has demonstrated
Business type: Compounder · scaling but economically observable
Size is the strategy's, set against its own position and exposure limits.
At $73.44, KNSA requires a 15% five-year revenue growth rate to justify its enterprise value — less than the business already delivers, at 59%.
Growth is demonstrated at 4.0x the requirement (58.85% vs 14.80%), so the growth axis is not where the disagreement lives.
The value rests on an exit multiple of 15.4x, a terminal operating margin of 25% and a 7.6% cost of capital. Move any one of them materially and the conclusion moves with it, which is why the required-versus-demonstrated test above carries more weight here than the point value.
The strongest argument against this view: (1) SINGLE-PRODUCT SAFETY OR LABEL ACTION ON RILONACEPT — ARCALYST is 100.0% of revenue and 99.80% United States, and KPL-387/KPL-1161 are the same IL-1 pathway, so the pipeline is not a hedge against this cause.
| Question | Evidence-based conclusion |
|---|---|
| What drives the business? | Growth is demonstrated at 4.0x the requirement (58.85% vs 14.80%), so the growth axis is not where the disagreement lives. |
| What do we forecast? | Revenue growth of 59% demonstrated; a terminal operating margin of 25%; an exit multiple of 15.4x. |
| What does Street forecast? | Not determined — no consensus estimates are joined to this record |
| Where do we differ? | On terminal margin, the difference between what the price requires and what the business has demonstrated is +10.0 percentage points. |
| What is it worth? | Twelve-month target $72.90, -1% from the struck price. Scenario-weighted expected return net of costs -0.7%. |
| Why now? | Date not announced — no dated event that would resolve the disagreement is on file |
| Date or window | Event | Thesis confirmed if | Thesis weakened or refuted if |
|---|---|---|---|
| 27 October 2026 | Next results (date estimated, not issuer-confirmed) | Revenue and margin in line with, or above, the house path | A miss that moves the full-year path below the guided floor |
Dates marked as estimated are drawn from the company’s own reporting cadence, not from an announcement.
(1) SINGLE-PRODUCT SAFETY OR LABEL ACTION ON RILONACEPT — ARCALYST is 100.0% of revenue and 99.80% United States, and KPL-387/KPL-1161 are the same IL-1 pathway, so the pipeline is not a hedge against this cause. (2) EXCLUSIVITY CLIFF — ARCALYST's US orphan marketing exclusivity, granted March 2021 for seven years, expires ~MARCH 2028, roughly 19 months into the five-year implied path, while 80.1% of EV is terminal value.
Estimated probability 8%, against the 12% level at which the position would be resized. It sits within that level.
Falsifiable and fundamental — not one of them is a price condition.
Trim or exit when forward expected return falls below 0.0% net of costs, or when price reaches the 12-month target and the multiple has not been re-validated against a higher NTM revenue base. On approach to the $72.90 target the case is reviewed rather than added to; a target reached is a reason to re-examine the position, not to hold it by default. The position is trimmed once forward expected return falls below 0% net of costs, because the capital has a better use elsewhere in the book.
| Criteria | Status | Investment meaning |
|---|---|---|
| Quality | Met | Is the business worth owning under its declared economic type? |
| Valuation | Met | Is the operating path required by today's price achievable? |
| Liquidity | Met | Can the intended position be built and exited in the right vehicle? |
| Downside | Met | (1) SINGLE-PRODUCT SAFETY OR LABEL ACTION ON RILONACEPT — ARCALYST is 100.0% of revenue and 99.80% United States, and KPL-387/KPL-1161 are the same IL-1 pathway, so the pipeline is not a hedge against this cause. |
| Momentum | Not determined | Does price action support or complicate entry timing? Not established on the evidence on file. |
| Catalyst | Not determined | Is there a dated event that resolves the disagreement? Not established on the evidence on file. |
| Consensus | Not determined | Is the house-versus-Street disagreement identified and quantified? Not established on the evidence on file. |
Quality, valuation and liquidity can prevent a position on their own. The remaining four inform timing, sizing and monitoring, and never reject an investment by themselves.
The strongest case for mispricing is that the business already delivers +10.0 percentage points more growth than the price requires. The most important unresolved uncertainty is the permanent-loss mechanism: (1) SINGLE-PRODUCT SAFETY OR LABEL ACTION ON RILONACEPT — ARCALYST is 100.0% of revenue and 99.80% United States, and KPL-387/KPL-1161 are the same IL-1 pathway, so the pipeline is not a hedge against this cause. The next evidence that should change the portfolio decision is the next scheduled results, or a daily close below $63.43, which forces an immediate review.